AGIO

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.

Agios Pharmaceuticals, Inc. (AGIO) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (2.9) A (4.2) B (3.2) C+ (2.8) C+ (2.6) B (3.2)
2026-11-10 B- (2.9) A (4.2) B (3.2) B- (3.0) C+ (2.6) B (3.2)
2026-11-03 B- (2.9) A- (4.1) B (3.2) B- (3.0) C+ (2.7) B (3.2)
2026-10-27 B- (2.9) A- (4.1) B (3.2) B- (3.0) C+ (2.6) B (3.2)
2026-10-20 B- (2.9) A- (4.1) B (3.2) C+ (2.7) C+ (2.6) B- (3.1)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe